Tag: Immuno
OSE Immuno: end of recruitment of a trial for UC
(CercleFinance.com) – OSE Immunotherapeutics today announces the end of recruitment in the Phase 2b clinical trial evaluating the IL-7 receptor antagonist monoclonal antibody Lusvertikimab (OSE-127) in patients with ulcerative colitis…
OSE Immuno: end of recruitment of a trial for RCH – 03/18/2024 at 08:01
(CercleFinance.com) – OSE Immunotherapeutics today announces the end of recruitment in the Phase 2b clinical trial evaluating the IL-7 receptor antagonist monoclonal antibody Lusvertikimab (OSE-127) in patients with ulcerative colitis…
Ose immuno: End of recruitment of a trial for UC
Receive the value of the day for free every morning The data collected is essential for this processing and is intended for the relevant services of BFM Bourse and, where…
OSE Immuno: the title soars, partnership with AbbVie – 02/28/2024 at 11:45
(CercleFinance.com) – OSE Immunotherapeutics shares soared on the Paris Stock Exchange on Wednesday following the signing of a strategic partnership with the American biopharmaceutical group AbbVie. Around 11:30 a.m., the…
OSE Immuno: positive interim analysis of a study – 11/12/2023 at 2:25 p.m.
(CercleFinance.com) – OSE Immunotherapeutics announces that it has presented a positive interim analysis of data from the phase 1/2 clinical trial relating to the first use in kidney transplantation of…
Ose immuno: Collaboration agreement with GenDx
Read also (CercleFinance.com) – OSE Immunotherapeutics announces a collaboration agreement with GenDx (Eurobio Scientific Group) to develop and validate a companion diagnostic test (CDx) as part of the preparation of…
OSE Immuno: collaboration agreement with GenDx – 11/21/2023 at 6:09 p.m.
(CercleFinance.com) – OSE Immunotherapeutics announces a collaboration agreement with GenDx (Eurobio Scientific Group) to develop and validate a companion diagnostic test (CDx) as part of the preparation of the pivotal…
OSE Immuno: first positive results for an antibody – 10/24/2023 at 10:58
(CercleFinance.com) – OSE Immunotherapeutics was among the biggest risers on the Paris Stock Exchange this Tuesday after the biotechnology company announced the first positive clinical results on its new monoclonal…
OSE Immuno: ‘very promising’ results from a clinical trial – 10/16/2023 at 09:37
(CercleFinance.com) – OSE Immunotherapeutics reported on Monday ‘very promising’ first results concerning a phase 1/2 clinical trial evaluating its monoclonal antibody in patients with solid tumors. According to the biotech,…
Ose immuno: ‘very promising’ results from a clinical trial
Read also (CercleFinance.com) – OSE Immunotherapeutics reported on Monday ‘very promising’ first results concerning a phase 1/2 clinical trial evaluating its monoclonal antibody in patients with solid tumors. According to…
OSE Immuno presents advances in its research programs at upcoming international conferences CICON International Conference
By Hector Chaunu Published on 09/20/2023 at 7:35 a.m. (Boursier.com) — OSE Immunotherapeutics SA announces that the scientific…
OSE Immuno: obtaining public aid – 08/01/2023 at 08:00
(CercleFinance.com) – OSE Immunotherapeutics announces that it has received innovation aid of 200,000 euros from the French Government and the Pays de la Loire Region, as part of the ‘France…